{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:20:09Z","timestamp":1790360409235,"version":"4.1.0"},"reference-count":50,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novartis Pharmaceutical Corporation"},{"name":"RTI Health Solutions"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,4,30]]},"DOI":"10.2217\/fon-2018-0871","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T10:44:37Z","timestamp":1548758677000},"page":"1255-1268","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["Patient Preferences for Treatment of Metastatic Melanoma"],"prefix":"10.1080","volume":"15","author":[{"given":"Carol","family":"Mansfield","sequence":"first","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Ndife","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["East Hanover, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["East Hanover, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gallaher","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Ghate","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation","place":["East Hanover, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.4877"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2016.1184644"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.06.47"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.2016017150"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.43"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-016-0421-5"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000405"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.06.028"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.1126"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.2311"},{"key":"e_1_3_4_13_1","unstructured":"US FDA . Patient preference information \u2013 voluntary submission review in premarket approval applications humanitarian device exemption applications and de novo requests and inclusion in decision summaries and device labeling: guidance for industry food and drug administration staff and other stakeholders. www.fda.gov\/downloads\/MedicalDevices\/DeviceRegulationandGuidance\/GuidanceDocuments\/UCM446680.pdf."},{"key":"e_1_3_4_14_1","unstructured":"US FDA . Enhancing benefit\u2013risk assessment in regulatory decision-making. www.fda.gov\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/ucm326192.htm."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-014-4044-2"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017831"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0000000000000557"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S140226"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9656-2"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(16)31820-2"},{"issue":"6","key":"e_1_3_4_25_1","first-page":"LBA40","article-title":"Three-year estimate of overall survival in COMBI-v, a randomized Phase III study evaluating first-line debrafenib + trametinib in patients with unresectable or metastatic BRAF V600E\/K-mutant cutaneous melanoma","volume":"27","author":"Robert C","year":"2016","unstructured":"Robert C , KaraszewskaB, SchachterJet al. Three-year estimate of overall survival in COMBI-v, a randomized Phase III study evaluating first-line debrafenib + trametinib in patients with unresectable or metastatic BRAF V600E\/K-mutant cutaneous melanoma. Ann. Oncol.27(Suppl. 6), LBA40 (2016).","journal-title":"Ann. Oncol."},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx176"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"e_1_3_4_34_1","volume-title":"Sawtooth Software Conference Proceedings","author":"Kuhfeld W","year":"1997","unstructured":"Kuhfeld W . Efficient experimental designs using computerized searches. Presented at: Sawtooth Software Conference Proceedings. Seattle, WA, USA, August 1997."},{"key":"e_1_3_4_35_1","unstructured":"Kuhfeld W . Marketing research methods in SAS: experimental design choice conjoint and graphical techniques. SAS Institute Inc. NC USA (2010). http:\/\/support.sas.com\/techsup\/technote\/mr2010.pdf."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/002224379403100408"},{"key":"e_1_3_4_37_1","unstructured":"Chrzan K OrmeB. An overview and comparison of design strategies for choice-based conjoint analysis (2000). www.sawtoothsoftware.com\/download\/techpap\/desgncbc.pdf."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.921611"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781107337855"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2006.04.002"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-013-0620-5"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300525"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.04.011"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.03.014"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511805271"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/1-4020-3684-1_7"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511610356"},{"key":"e_1_3_4_48_1","unstructured":"The MaxDiff System Technical Paper (2013). www.sawtoothsoftware.com\/download\/techpap\/maxdifftech.pdf."},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.2307\/3147300"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reseneeco.2010.01.006"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecolecon.2007.02.005"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1159\/000448904"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:45:14Z","timestamp":1762958714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,4,30]]}},"alternative-id":["10.2217\/fon-2018-0871"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0871","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}